UK cell & gene therapy: From investment to impact. A fireside chat with Sam Goldsmith & Jim Faulkner

What does it take to turn a promising cell and gene therapy idea into an investable company? In this discussion, Sam Goldsmith, Head of Venture Creation at CGT Catapult, speaks with Dr Jim Faulkner, Chair of the Board at CGT Catapult, about the UK cell and gene therapy investment landscape. They discuss the pre-seed journey, what investors look for in early-stage companies, the UK’s competitiveness in attracting investment, and the opportunities and challenges shaping the future of the sector. Watch the full conversation for insights into the route from early innovation to investment and commercialisation.